How epileptogenic are the recent antibiotics?

Acta Clinica Belgica

Volumn 54, Issue 2, 1999, Pages 80-87

  Hantson, Ph ^a   Leonard F ^b   Maloteaux, J M ^a   Mahieu, P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Laboratoire LBS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAPENEM; CEPHALOSPORIN; MONOBACTAM; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE DERIVATIVE;

AGE; ANTIBIOTIC THERAPY; ARTICLE; DRUG METABOLISM; EPILEPTOGENESIS; HUMAN; MODEL; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; RISK ASSESSMENT; RISK FACTOR; SEIZURE; STRUCTURE ACTIVITY RELATION;

EID: 0345518027     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1999.11754213     Document Type: Article

References (89)

1. Wallace KL. Antibiotic-induced convulsions. Crit Care Clin 1997; 13: 741-62.
2. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 1991; 27: 405-25.
3. Moulton RP. Neurotoxicity of penicillin. J Antimicrob Chemother 1980; 6: 161-72.
4. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84: 911-8.
5. Williams PD, Bennett DB, Comereski CR. Animal model for evaluating the convulsive liability of β-lactam antibiotics. Antimicrob Agents Chemother 1988; 32: 758-60.
6. Antoniadis A, Muller WE, Wollert U. Inhibition of GABA and benzodiazepine receptor binding by penicillins. Neurosci Lett 1980; 18: 309-12.
7. De Boer T, Stoof JC, Van Duyn H. Effect of penicillin on transmitter release from rat cortical tissue. Brain Res 1980; 192: 296-300.
8. De Sarro A, De Sarro GB, Ascioti C, Nisticò G. Epileptogenic activity of some β-lactam derivatives: structure activity relationship. Neuropharmacology 1989; 28: 359-65.
9. Hori S, Kurioka S, Matsuda M, Shimada J. Inhibitory effect of cephalosporins on γ-aminobutyric acid receptor binding in rat synaptic membranes. Antimicrob Agents Chemother 1985; 27: 650-1.
10. Shimada J, Hori S, Kanemitsu K, Shoji Y, Nakashio S, Yanagawa A. A comparative study on the convulsant activity of carbapenems and beta-lactams. Drugs Exp Clin Res 1992: 18: 377-81.
11. Tsuji A, Sato H, Kume Y et al. Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob Agents Chemother 1988; 32: 190-4.
12. Johnson HC, Walker AE. Intraventricular penicillin: a note of warning. JAMA 1945; 127: 217-9.
13. Bloomer HA, Barton LJ, Maddock RK Jr. Penicillin induced encephalopathy in uremic patients. JAMA 1967; 200: 121-3.
14. Fossieck B, Parker RH. Neurotoxicity during intravenous infusion of penicillin, a review. J Clin Pharmacol 1974; 14: 504-12.
15. Boston Collaborative Drug Surveillance Program: Drug induced convulsions. Lancet 1972; 2: 677-9.
16. Hodgman T, Dasta JF, Armstrong DK, Visconti JA, Reilley TE. Ampicillin-associated seizures. South Med J 1984; 77: 1323-5.
17. Shaffer CL, Davey AM, Ransom JL, Brown YL, Gal P. Ampicillin-induced neurotoxicity in very-low-birth-weight neonates. Ann Pharmacother 1998; 32: 482-484.
18. Bechtel TP, Slaughter RL, Moore TD. Seizures associated with high cerebrospinal fluid concentrations of cefazolin. Am J Hosp Pharm 1980: 37: 271-3.
19. Yost RL, Lee JD O'Leary JP. Convulsions associated with sodium cefazolin: a case report. Am Surg 1977; 43: 417-20.
20. Gardner ME, Fritz WL, Hyland RN. Antibiotic-induced seizure: A case attributed to cefazoline. Drug Intell Clin Pharm 1978; 12: 268-71.
21. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins: an update. Drug Saf 1993; 9: 132-42.
22. Rains CP, Bryson HM, Peters DH. Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995; 49: 577-617.
23. Jackson GD, Berkovic SF. Ceftazidime encephalopathy: absence status and toxic hallucinations. J Neural Neurosurg Psychiatry 1992; 55: 333-4.
24. Al-Zahawi MRF, Sprott MS, Hendrick DJ. Hallucinations in association with ceftazidime (letter). BMJ 1988; 297: 858.
25. Hillsley RE. Massey EW. Truncal asterixis associated with ceftazidime, a third-generation cephalosporin. Neurology 1991;41:2008.
26. Klion AD, Kallsen J, Cowl CT. Ceftazidime-related non-convulsive status epilepticus. Arch Intern Med 1994; 154: 586-9.
27. Ceftazidime, penicillin and the epilepsies (Editorial). Lancet 1992; 340: 400-1.
28. Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med 1996; 100(6A): 68S-75S.
29. Grøndahl TØ, Langmoen IA. Epileptogenic effect of antibiotic drugs. J Neurosurg 1983; 78: 938-43.
30. Gerald MC, Massey J, Spadaro DC. Comparative convulsant activity of various penicillins after intracerebral injection in mice. J Pharm Pharmacol 1973; 25: 104-8.
31. Kamei C, Sunami A, Tasaka K. Epileptogenic activity of cephalosporins in rats and their structure-activity relationship. Epilepsia 1983; 24: 431-9.
32. Hori S, Kanemitsu K, Shimada J. Effects of cephalosporins on gamma-aminobutyric acid receptor binding with or without non-steroidal anti-inflammatory drugs. J Antibiot Tokyo 1993; 46: 1145-8.
33. Ayroza Galvao PA, Milstein Kuschnaroff TM, Mimica IM, Maassen S, Barbosa Jr SP, Cavalcante NJ, Lorenco R, Mimica LM, Martino MD. Aztreonam in the treatment of bacterial meningitis. Chemotherapy 1989; 35 (Suppl 1): 39-44.
34. Alvan G, Nord CE. Adverse effects of monobactams and carbapenems. Drug Saf 1995; 12: 305-13.
35. De Sarro A, Ammendola D, Zappala M, Grasso S, De Sarro GB. Relationship between structure and convulsant properties of some beta-lactam antibiotics following the intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995; 39: 232-7.
36. De Sarro A, Naccari F, Imperatore C, De Sarro GB. Comparative epileptogenic properties of two monobactam derivatives in C57, Swiss and DBA/2 mice. J Antimicrob Chemother 1996; 38: 475-84.
37. Brotherton TJ, Kelber RL. Seizure-like activity associated with imipenem. Clin Pharmacy 1984; 3: 536-40.
38. Tse ST, Vera FH, Desai DV. Seizure-like activity associated with imipenem-cilastatin. Drug Intell Clin Pharm 1987; 21: 629-60.
39. Bodey GP. Elting L. Jones P, Alvarez ME, Rolston K, Fainstein V. Imipenem-cilastatin therapy of infections in cancer patients. Cancer 1987; 60: 225-62.
40. Eng RHK, Munsif AN, Yongco BG, Smith SM. Chmel H. Seizure propensity with imipenem. Arch Intern Med 1989; 149: 1881-3.
41. Leo RJ, Ballow CH. Seizure activity associated with imipenem use: clinical case reports and review of the literature. Ann Pharmacother 1991; 25: 351-4.
42. Calandra GB, Brown KR, Grad LC. Ahonkhal VI, Wang C, Aziz MA. Review of adverse experiences and tolerability in the first 2516 patients treated with imipenem/cilastatin. Am J Med 1985; 78 (Suppl 6A): 73-8.
43. Calandra GB, Ricci FM, Wang C, Brown KR. The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials. J Clin Pharmacol 1984; 3: 536-40.
44. Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15: 87-90.
45. Pestotnick SL, Classen DC. Evans CR et al. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother 1993; 27: 497-500.
46. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 15: 849-59.
47. Rolston KV, Berkey P. Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283-91.
48. Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38: 547-57.
49. Shimada J, Hori S, Kanemitsu K, Shoji Y, Nakashio S. Yanagawa A. A comparative study on the convulsant activity of carbapenems and beta-lactams. Drugs Exp Clin Res 1992; 18: 377-81.
50. Wiseman LR, Wagstaff A, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50: 73-101.
51. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 (Suppl A): 207-23.
52. Day IP, Goudie J, Nishiki K, Williams PD. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995; 76: 239-43.
53. Patel JB, Gilles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989; 24 (Suppl A): 307-9.
54. Kamei C. Kitazumi K, Tsujimoto S, Yoshida T, Tasaka K. Comparative study of certain antibiotics on epileptogenic property, including (1 Rpi, 5S, 6S)-2-[(6,7-dihydro-5H-pyrazol[1,2-a] [1,2,4]triazolium-6-yl)]thio-6-[(R)-l-hydroxyethyl]l-methyl-carbapenem-3- carboxylate (LJC 10627), a carbapenem antibiotic with broad antimicrobial spectrum. J Pharmacobio Dyn 1991; 14: 509-17.
55. A, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother 1993; 37: 199-202.
56. Dagan R, Velghe L, Rodda JL. Klugman KP. Penetration of meropenem into the cerebrospinal fluid of patients with inflammed meninges. J Antimicrob Chemother 1994; 34: 175-9.
57. Kurihara A, Hisaoka A, Mikuni N, Kamoshida K. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: correlation to concentration in central nervous system. J Pharmacobiodyn 1992; 15: 325-32.
58. Sunagawa M, Matsumura H, Sumita Y, Nouda H. Structural features resulting in convulsive activity of carbapenems compounds: effect of C-2 side chain. J Antibiot Tokyo 1995; 48: 408-16.
59. De Sarro GB, Ammendola D, De Sarro A. Effects of some excitatory amino acid antagonists on imipenem-induced seizures in DBA/2 mice. Brain Res 1995; 671: 131-40.
60. Ball P. Adverse reactions and interactions of fluoroquinolones. Clin Invest Med 1989; 12: 28-34.
61. Halkin H. Adverse effects of fluoroquinolones. Rev Infect Dis 1988; 10 (Suppl 1): S258-61.
62. Arcieri GM, Becker N, Esposito B, Griffith E, Heyd A, Neumann C, O'Brien B, Schacht P. Safety of intravenous ciprofloxacin. Am J Med 1989; 87 (Suppl 5A): 92S-97S.
63. Gonzalez JP, Henwood JM. Pefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1989; 37: 628-68.
64. Boerema J, Boll B, Muytjens H, Branolte J. Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother 1985; 16: 211-17.
65. Boerema JB, Pauwels R, Scheepers J, Crombach W. Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother 1986; 17 (Suppl B): 103-9.
66. Anastasio GD, Menscer D, Little JM Jr. Norfloxacin and seizures (letter). Ann Intern Med 1988; 108: 169-70.
67. Slavich IL, Gleffe RF, Haas EJ. Grand Mal epileptic seizures during ciprofloxacin therapy. JAMA 1989; 261: 558-9.
68. Schwartz MT, Calvert JF. Potential neurologic toxicity related to ciprofloxacin. Drug Intell Clin Pharm 1990; 24: 138-40.
69. Bader MB. Role of ciprofloxacin in fatal seizures. Chest 1992; 101: 883-4.
70. Lucet JC, Tilly H, Lerebours G, Gres JJ, Piguet H. Neurologic toxicity related to pefloxacin (letter). J Antimicrob Chemother 1988; 21: 811-2.
71. Romano C, Cristina T, Daniela C, Mario C. Epileptic attacks associated with pefloxacin treatment in a patient on CAPD (letter). Clin Nephrol 1989; 32: 48-9.
72. Simpson KJ, Brodie MJ. Convulsions related to enoxacin. Lancet 1985; 2: 161.
73. Parent M, LeBel M. Meta-analysis of quinolone-theophylline interactions. Drug Intell Clin Pharm 1991; 25: 191-4.
74. A receptors by 4-quinolones. J Antimicrob Chemother 1993; 31: 457-62.
75. Robson RA. The effects of quinolones on xanthine pharmacokinetics. Am J Med 1992; 92: 22S-25S.
76. Hasegawa T, Kuzuya T, Apichartpichean R, Nadai M, Nitta A, Takagi K, Nabeshima T. Structure-related inhibitory effect of quinolones on alkyl-xanthine elimination in rats. Pharmacol Toxicol 1991; 69: 5-8.
77. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother 1996; 37 (Suppl A): 41-55.
78. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 1990; 26 (Suppl B): 219-25.
79. A receptor complex. Br J Clin Pharmacol 1990; 30: 63-70.
80. Akahane K, Sekiguchi M, Une T, Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with γ-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989; 33: 1704-8.
81. Akahane K, Kimura Y. Tsutomi Y, Hayakawa I. Possible intermolecular interaction between quinolones and biphenylacetic acid inhibits γ-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1994; 38: 2323-9.
82. Segev S, Rehavi M, Rubinstein E. Quinolones, theophylline, and diclofenac interactions with the γ-aminobutyric acid receptor. Antimicrob Agents Chemother 1988; 32: 1624-6.
83. Christ W, Gindler K, Gruene S et al. Interactions of quinolones with opioids and fenbufen, a nonsteroidal antiinflammatory drug: involvement of dopaminergic transmission. Rev Infect Dis 1989; 11 (Suppl 5): S1393-4.
84. A receptor in dissociated hippocampal cells of rat. J Neurophysiol 1991 ; 66: 497-504.
85. Vancutsem PM, Schwark WS. Effects of fluoroquinolone antimicrobials alone and in conjunction with theophylline on seizures in amygdaloid kindled rats. Mechanistic and pharmacokinetic study. Epilepsy Res 1992; 13: 59-71.
86. De Sarro A, Ammendola D, De Sarro G. Effects of some quinolones on imipenem-induced seizures in DBA/2 mice. Gen Pharmacol 1994; 25: 369-79.
87. De Sarro A, Zappala M, Chimirri A, Grasso S. De Sarro GB. Quinolones potentiate cefazolin-induced seizures in DBA/2 mice. Antimicrob Agents Chemother 1993; 37: 1497-503.
88. Williams PD, Helton DR. The proconvulsive activity of quinolone antibiotics in an animal model. Toxicol Lett 1991; 58: 23-8.
89. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42: 1831-6.